Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001246141 | SCV001419481 | likely benign | Nemaline myopathy 2 | 2023-12-30 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001246141 | SCV001451492 | uncertain significance | Nemaline myopathy 2 | 2019-03-22 | criteria provided, single submitter | clinical testing | The NEB c.23894C>A (p.Thr7965Asn) variant is a missense variant. A literature search was performed for the gene, cDNA change, and amino acid change. No publications were found based on this search. Control data are unavailable for this variant, which is reported at a frequency of 0.000421 in the Other population of the Genome Aggregation Database. Based on the limited evidence, the p.Thr7965Asn variant is classified as a variant of uncertain significance for nemaline myopathy. |
Ambry Genetics | RCV002564101 | SCV003746991 | uncertain significance | Inborn genetic diseases | 2022-09-27 | criteria provided, single submitter | clinical testing | The c.18686C>A (p.T6229N) alteration is located in exon 139 (coding exon 137) of the NEB gene. This alteration results from a C to A substitution at nucleotide position 18686, causing the threonine (T) at amino acid position 6229 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003130227 | SCV003812217 | uncertain significance | not provided | 2023-10-26 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001246141 | SCV002083998 | uncertain significance | Nemaline myopathy 2 | 2021-03-29 | no assertion criteria provided | clinical testing |